{"nctId":"NCT01421342","briefTitle":"VA Augmentation and Switching Treatments for Improving Depression Outcomes","startDateStruct":{"date":"2012-12"},"conditions":["Major Depressive Disorder"],"count":1522,"armGroups":[{"label":"Switching: Bupropion-SR","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Switching: Bupropion-SR"]},{"label":"Augmenting: Antidepressant + Bupropion-SR","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Augmenting: Antidepressant + Bupropion-SR"]},{"label":"Augmenting: Antidepressant + Aripiprazole","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Augmenting: Antidepressant + Aripiprazole"]}],"interventions":[{"name":"Switching: Bupropion-SR","otherNames":[]},{"name":"Augmenting: Antidepressant + Bupropion-SR","otherNames":[]},{"name":"Augmenting: Antidepressant + Aripiprazole","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* DSM-IV diagnosis of single or recurrent, non-psychotic, major depressive disorder\n* Currently taking a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) or mirtazapine for major depressive disorder\n* Need for \"next-step\" treatment based on documented suboptimal outcome from current antidepressant treatment for major depressive episode (at least 6 weeks treatment with a QIDS-C16 \\>= 16 or at least 8 weeks with a QIDS-C16 \\>= 11; and at least 3 weeks at a stable \"optimal\" dose\n* Age: 18 years of age or older\n\nExclusion Criteria:\n\n* Prior inadequate response after an adequate treatment trial or clear cut intolerance to either of the study medications (aripiprazole or bupropion)\n* Current treatment with bupropion, aripiprazole or any other antipsychotic agent\n* Lifetime history of bipolar disorder, schizophrenia, schizoaffective disorder, or psychosis not otherwise specified\n* Current diagnosis of Dementia\n* Current diagnosis of an eating disorder or a seizure disorder\n* High suicide risk currently requiring acute intervention (other than outpatient treatment of depression)\n* Unstable, serious medical condition or one requiring acute medical treatment, or anticipation of hospitalization for extended care\n* Requiring immediate hospitalization for psychiatric disorders\n* Physiologic substance dependence requiring detoxification (excluding nicotine) in the past 30 days (substance abuse is not an exclusion criteria)\n* Taking any concomitant medication that contraindicates any of treatment options or augmenting agents known to have an antidepressant effect\n* Concurrent or recent participation (within the last 30 days) in another conflicting clinical trial with a mental health, investigational drug, or medical device intervention\n* Female - pregnant or lactating or planning to become pregnant\n* Patient was not able or willing to provide informed consent; or changed mind about participating prior to randomization\n* Patient was not referred to the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Rate of Protocol Remission of Symptoms of Major Depressive Disorder","description":"Remission of symptoms of major depression during the acute treatment phase (12 weeks) defined as a sustained clinician-rated Quick Inventory of Depressive Symptoms (QIDS-C16) of \\<= 5 for two consecutive visits.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"136","spread":null},{"groupId":"OG002","value":"146","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Protocol Relapse of Symptoms of Major Depression After Achieving Remission in the Acute Phase","description":"Relapse in symptoms of major depression defined as a QIDS-C16 =\\> 11 among those achieving remission in the acute phase.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Protocol Response as Reduction in Symptoms of Major Depression (>= 50% Reduction in QIDS-C)","description":"Response measured as reduction in symptom score for major depression defined as: 1. a reduction in QIDS-C16 of 50% or greater","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"319","spread":null},{"groupId":"OG001","value":"332","spread":null},{"groupId":"OG002","value":"375","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Protocol Response Measured as a Change in Clinical Global Impression (CGI) - Improvement Scale","description":"Clinical assessment of a participant's level of depression and treatment response assessed by the Clinical Global Impression - Improvement (CGI -I) Scale, a 7-point clinician rating scale of improvement from baseline in severity of depression (Guy 1976). A secondary outcome measure of response was defined as achieving a score of 2 (much improved) or 1 (very much improved).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"356","spread":null},{"groupId":"OG001","value":"376","spread":null},{"groupId":"OG002","value":"400","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":52,"n":511},"commonTop":["Nervous system disorders","Psychiatric disorders","Gastrointestinal disorders","Metabolism and nutrition disorders","General disorders and administration site conditions"]}}}